Consensus Guidelines for the Management of Locally Advanced and Metastatic Renal Cell Carcinoma by the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology for 2025 - Takeaways - MDSpire

Consensus Guidelines for the Management of Locally Advanced and Metastatic Renal Cell Carcinoma by the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology for 2025

  • By

  • Darren M. C. Poon

  • Philip W. K. Kwong

  • Samson Y. S. Chan

  • Brian S. H. Ho

  • Martin H. C. Lam

  • K. S. Law

  • Angus K. C. Leung

  • Clarence L. H. Leung

  • David K. W. Leung

  • W. K. Ma

  • Barry B. W. Wo

  • Kenneth C. W. Wong

  • Philip Y. Wu

  • Peter K. F. Chiu

  • April 23, 2026

  • 0 min

Share

  • 1

    The Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology updated management guidelines for locally advanced and metastatic renal cell carcinoma.

  • 2

    A panel of 14 experts established 42 consensus statements through Delphi meetings, focusing on various treatment aspects of renal cell carcinoma.

  • 3

    The updated guidelines emphasize adjuvant therapy for locally advanced RCC and immunotherapy-based combinations for metastatic RCC.

  • 4

    New recommendations include active surveillance for mRCC patients with favorable prognosis and the introduction of belzutifan as a treatment option.

  • 5

    These consensus statements aim to provide practical references for clinicians managing renal cell carcinoma in Hong Kong and the Asia-Pacific region.

Original Source(s)

Consensus Guidelines for the Management of Locally Advanced and Metastatic Renal Cell Carcinoma by the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology for 2025

  • by Darren M. C. Poon, Philip W. K. Kwong, Samson Y. S. Chan, Brian S. H. Ho, Martin H. C. Lam, K. S. Law, Angus K. C. Leung, Clarence L. H. Leung, David K. W. Leung, W. K. Ma, Barry B. W. Wo, Kenneth C. W. Wong, Philip Y. Wu, Peter K. F. Chiu

  • April 23, 2026

Related Content

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications